[Click e-Stock] "GC Wellbeing Expected to Grow with Placenta Injection Laennec"

On May 30, Hana Securities predicted that the placenta injection 'Laennec' would drive growth for GC Wellbeing.

In the first quarter, GC Wellbeing recorded sales of 34.8 billion KRW and operating profit of 5 billion KRW. These figures represent increases of 5.3% and 81.6%, respectively, compared to the same period last year.

Choi Jaeho, a researcher at Hana Securities, stated, "There are two main reasons for expecting growth in the placenta injection Laennec," adding, "The company is currently conducting Phase 3 clinical trials to expand its indications." He further explained, "After completing the trials this year, they plan to commercialize the product starting next year."

He also emphasized, "The company is making a full-scale entry into the Chinese market," and continued, "Laennec received fast-track approval in September last year in Hainan Province, a special medical zone in China, becoming the first Korean company to begin selling placenta injections in China."

Choi estimated, "This year's total sales forecast for Laennec is 45 billion KRW," and added, "Sales from Hainan Province in China are expected to reach 5 billion KRW." He also noted, "Last year, the company achieved 39 billion KRW in sales in Korea alone," and expressed optimism that the actual results could exceed expectations.